CR20240147A - Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t - Google Patents

Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t

Info

Publication number
CR20240147A
CR20240147A CR20240147A CR20240147A CR20240147A CR 20240147 A CR20240147 A CR 20240147A CR 20240147 A CR20240147 A CR 20240147A CR 20240147 A CR20240147 A CR 20240147A CR 20240147 A CR20240147 A CR 20240147A
Authority
CR
Costa Rica
Prior art keywords
drug
treating
preparation
cell lymphoma
ezh2 inhibitor
Prior art date
Application number
CR20240147A
Other languages
English (en)
Inventor
Xiaojing Zhang
Weiwei Wang
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of CR20240147A publication Critical patent/CR20240147A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso de un inhibidor de EZH2 en la preparación de un fármaco para el tratamiento de linfoma de linfocitos T. Específicamente, la presente invención se refiere al uso de un compuesto según se representa en la fórmula (I) o una sal farmacéuticamente aceptable del mismo en la preparación de un fármaco para el tratamiento de linfoma de linfocitos T.
CR20240147A 2021-08-30 2022-08-30 Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t CR20240147A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111001663 2021-08-30
PCT/CN2022/115763 WO2023030299A1 (zh) 2021-08-30 2022-08-30 一种ezh2抑制剂用于制备治疗t细胞淋巴瘤的药物的用途

Publications (1)

Publication Number Publication Date
CR20240147A true CR20240147A (es) 2024-09-20

Family

ID=85411942

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240147A CR20240147A (es) 2021-08-30 2022-08-30 Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t

Country Status (16)

Country Link
US (1) US20240325371A1 (es)
EP (1) EP4393490A4 (es)
JP (1) JP2024530310A (es)
KR (1) KR20240056564A (es)
CN (1) CN117956995A (es)
AU (1) AU2022340500A1 (es)
CA (1) CA3230149A1 (es)
CL (1) CL2024000593A1 (es)
CO (1) CO2024003923A2 (es)
CR (1) CR20240147A (es)
IL (1) IL311097A (es)
MA (1) MA65131B1 (es)
MX (1) MX2024002538A (es)
PE (1) PE20240881A1 (es)
TW (1) TW202327597A (es)
WO (1) WO2023030299A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323820B1 (en) * 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CN105102432B (zh) * 2012-10-15 2019-01-04 Epizyme股份有限公司 经取代的苯化合物
WO2017084494A1 (zh) * 2015-11-19 2017-05-26 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN108314677B (zh) * 2017-01-17 2020-06-30 安徽中科拓苒药物科学研究有限公司 一种ezh2抑制剂及其用途
MY198008A (en) * 2017-05-18 2023-07-25 Jiangsu Hengrui Medicine Co Crystal of benzofuran derivative free base and preparation method
CN110179796B (zh) * 2018-02-23 2023-01-24 江苏恒瑞医药股份有限公司 一种苯并呋喃类衍生物的组合物及制备方法
WO2020192650A1 (zh) * 2019-03-25 2020-10-01 上海华汇拓医药科技有限公司 酰胺类化合物制备方法及其在医药领域的应用
WO2020228591A1 (zh) * 2019-05-10 2020-11-19 江苏恒瑞医药股份有限公司 一种6-取代氨基苯并呋喃化合物的制备方法
TW202126302A (zh) * 2019-09-30 2021-07-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｅｚｈ２抑制劑與免疫檢查點抑制劑、酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途
WO2021063331A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途

Also Published As

Publication number Publication date
KR20240056564A (ko) 2024-04-30
US20240325371A1 (en) 2024-10-03
EP4393490A4 (en) 2025-08-27
MX2024002538A (es) 2024-03-19
CO2024003923A2 (es) 2024-06-27
WO2023030299A1 (zh) 2023-03-09
CN117956995A (zh) 2024-04-30
PE20240881A1 (es) 2024-04-24
IL311097A (en) 2024-04-01
AU2022340500A1 (en) 2024-04-11
CL2024000593A1 (es) 2024-07-05
CA3230149A1 (en) 2023-03-09
JP2024530310A (ja) 2024-08-16
EP4393490A1 (en) 2024-07-03
MA65131B1 (fr) 2025-05-30
MA65131A1 (fr) 2024-11-29
TW202327597A (zh) 2023-07-16

Similar Documents

Publication Publication Date Title
MX2024002538A (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t.
ZA202206923B (en) New methylquinazolinone derivatives
EA202193015A1 (ru) Ингибиторы cdk
MY207716A (en) Hiv inhibitor compounds
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2025010357A (es) Degradador de irak4, y uso del mismo
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2022008487A (es) Degradadores de smarca2-vhl.
ZA202401684B (en) Novel parp7 inhibitor and use thereof
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2023013715A (es) Regímenes de dosis de ecubectedina.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2024000999A (es) Antagonista de molécula pequeña de lpa1.
MX2024002674A (es) Derivados de tiadiazolona utiles como activadores de ampk.
MX2025008008A (es) Conjugados ligando-fármaco
GEP20257771B (en) Compounds and compositions as sppl2a inhibitors
MX2023013045A (es) Moduladores de exonucleasa i de tres reparaciones principales (trex1).
JOP20240119A1 (ar) مشتقات نافثيريدينون لمعالجة مرض أو اضطراب
MX2010002679A (es) Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
MX2024007629A (es) Compuesto como inhibidor de fak y uso del mismo.
MX2023002539A (es) Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv).
MX2024000087A (es) Compuestos tiazol-lactama-espiroheterociclicos y sus aplicaciones.